Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Zippia finds jobs where you're a top candidate and applies on your behalf.
Zoetis's peak revenue was $9.3B in 2024. The peak quarterly revenue was $2.4B in 2024(q3).
Zoetis's revenue increased from $4.3b in 2012 to $9.3B currently. That's a 113.47% change in annual revenue.
| Fiscal year / year | Zoetis revenue |
|---|---|
| 2012 | $4.3B |
| 2013 | $4.6B |
| 2014 | $4.8B |
| 2015 | $4.8B |
| 2016 | $4.9B |
| 2017 | $5.3B |
| 2018 | $5.8B |
| 2019 | $6.3B |
| 2020 | $6.7B |
| 2021 | $7.8B |
| 2022 | $8.1B |
| 2023 | $8.5B |
| 2024 | $9.3B |
How accurately did Zoetis' revenue projections match actual performance?
Zoetis saw the greatest revenue growth in 2021, when revenue increased by 16.49%.
Zoetis had the lowest revenue growth in 2015, when revenue changed by -0.42%.
| Year | Zoetis growth |
|---|---|
| 2013 | 5%↑ |
| 2014 | 5%↑ |
| 2015 | -0%↓ |
| 2016 | 3%↑ |
| 2017 | 9%↑ |
| 2018 | 10%↑ |
| 2019 | 7%↑ |
| 2020 | 7%↑ |
| 2021 | 16%↑ |
| 2022 | 4%↑ |
| 2023 | 6%↑ |
| 2024 | 8%↑ |
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2012 | - | - | - | $1.2B |
| 2013 | $1.1B | $1.1B | $1.1B | $1.3B |
| 2014 | $1.1B | $1.2B | $1.2B | $1.3B |
| 2015 | $1.1B | $1.2B | $1.2B | $1.3B |
| 2016 | $1.2B | $1.2B | $1.2B | $1.3B |
| 2017 | $1.2B | $1.3B | $1.3B | $1.5B |
| 2018 | $1.4B | $1.4B | $1.5B | $1.6B |
| 2019 | $1.5B | $1.5B | $1.6B | $1.7B |
| 2020 | $1.5B | $1.5B | $1.8B | $1.8B |
| 2021 | $1.9B | $1.9B | $2.0B | $2.0B |
| 2022 | $2.0B | $2.1B | $2.0B | $2.0B |
| 2023 | $2.0B | $2.2B | $2.2B | $2.2B |
| 2024 | $2.2B | $2.4B | $2.4B | $2.3B |
Do you work at Zoetis?
Is Zoetis transparent about its revenue structure?
| CEO | Juan Ramón Alaix |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 11,300 |
| Date Founded | 1952 |
| Headquarters | Parsippany-Troy Hills, New Jersey |
| Number of Locations | 10 |
| Revenue | $9.3B |
| Net Income | $2,114,000,000 |
| Gross Proft | $6.5B (2024) |
| EBITDA | $3.5B (2024) |
| PE Ratio | 18.14 |
| Tax Rate | 0.2% |
| Market Capitalization | $45.1B |
| Total Assets | $14,925,000,000 |
| Ticker | ZTS |
Zoetis's top competitor, Johnson & Johnson, earned an annual revenue of $88.8B.
Zoetis's smallest competitor is BASi with revenue of $23.5M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Merck | $90,328 | $64.2B | 74,000 | 1,380 |
| Hospira | $64,435 | $4.5B | 19,000 | - |
| Johnson & Johnson | $76,686 | $88.8B | 134,500 | 1,355 |
| Amgen | $93,349 | $33.4B | 22,000 | 565 |
| Gilead Sciences | $99,828 | $28.8B | 11,800 | 611 |
| Regeneron | $85,589 | $14.2B | 9,123 | 337 |
| Seagen | $85,008 | $2.0B | 900 | - |
| Alpharma | $61,984 | $350.0M | 2,000 | - |
| Novartis | $112,479 | $51.7B | 110,000 | 342 |
| Elanco | $70,606 | $4.4B | 10,200 | 118 |
Zippia gives an in-depth look into the details of Zoetis, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Zoetis. The employee data is based on information from people who have self-reported their past or current employments at Zoetis. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Zoetis. The data presented on this page does not represent the view of Zoetis and its employees or that of Zippia.
Zoetis may also be known as or be related to Whitehall Laboratories Inc, Zoetis, Zoetis Inc and Zoetis Inc.